DocGo Inc. (NASDAQ: DCGO) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims, $4 Million in Stock Sales

Schubert Jonckheer & Kolbe LLP reminds DocGo Inc. (NASDAQ: DCGO) investors that the firm is investigating potential legal claims relating to alleged false statements about the educational background of DocGo’s former CEO and the company’s business development efforts, and about $4 million in insider stock sales. Current shareholders are encouraged to contact us.

On March 28, 2025, Judge Katherine Polk Failla of the U.S. District Court for the Southern District of New York ruled that key claims in a securities fraud lawsuit against DocGo and its former CEO could move forward. The lawsuit alleges that between April 2022 and September 2023, DocGo misled investors by stating that its former CEO had a graduate degree in computer science and by misrepresenting DocGo’s efforts to enroll migrants in New York Medicaid programs and its business relationship with UnitedHealthcare. Judge Failla found that the complaint sufficiently alleged that the defendants made several “indisputably false” and misleading statements regarding these matters with an intent to defraud. During this period, company insiders sold about $4 million of DocGo stock. After the truth came out in September 2023 that DocGo’s former CEO never attended graduate school, DocGo did not enroll anyone in Medicaid, and that UnitedHealthcare did not have a contract with DocGo in New York, DocGo’s stock price fell 25%.

We are investigating potential wrongdoing by DocGo’s directors and officers in connection with these allegations.

If you own stock in DocGo, you may have legal options. To learn more fill out the form below.